Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2017

Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

view full story

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease
November 1, 2017

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

view full story

Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
November 1, 2017

Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting

view full story

Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017
October 23, 2017

Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017

view full story

Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
October 18, 2017

Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia

view full story

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
October 16, 2017

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer

view full story

Sutro Marks Two Drug Development Milestones
October 11, 2017

Sutro Marks Two Drug Development Milestones

view full story

Protagonist Therapeutics Prices Public Offering of Common Stock
October 11, 2017

Protagonist Therapeutics Prices Public Offering of Common Stock

view full story

Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders
October 3, 2017

Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders

view full story

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
September 20, 2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300

view full story

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor
September 20, 2017

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor

view full story

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
September 6, 2017

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

view full story

Celgene Corporation Exercised Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics
August 29, 2017

Celgene Corporation Exercised Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics

view full story

Coherus Biosciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420
August 28, 2017

Coherus Biosciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420

view full story

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment
August 24, 2017

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment

view full story

Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
August 24, 2017

Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting

view full story

Symic​ ​Bio​ ​Enrolls​ ​First​ ​Patient​ ​in​ ​MODIFY2​ ​Phase​ ​2​ ​Trial​ ​of​ ​SB-061​ ​for​ ​theTreatment​ ​of​ ​Osteoarthritis
August 23, 2017

Symic​ ​Bio​ ​Enrolls​ ​First​ ​Patient​ ​in​ ​MODIFY2​ ​Phase​ ​2​ ​Trial​ ​of​ ​SB-061​ ​for​ ​theTreatment​ ​of​ ​Osteoarthritis

view full story

Coherus Secures Private Placement from Temasek
August 21, 2017

Coherus Secures Private Placement from Temasek

view full story

Cavion Appoints Spyridon Papapetropoulos, M.D., Ph.D
August 15, 2017

Cavion Appoints Spyridon Papapetropoulos, M.D., Ph.D

view full story

Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting
August 11, 2017

Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting

view full story

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs
August 10, 2017

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

view full story

Data on VT-1161 for the Treatment of RVVC to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
August 8, 2017

Data on VT-1161 for the Treatment of RVVC to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

view full story

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
July 27, 2017

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting

view full story

Aeglea BioTherapeutics Announces Leadership Change
July 20, 2017

Aeglea BioTherapeutics Announces Leadership Change

view full story

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts
July 17, 2017

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts.

view full story

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
July 10, 2017

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

view full story

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry
July 5, 2017

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

view full story

Aileron Therapeutics Announces Pricing of Initial Public Offering
June 28, 2017

Aileron Therapeutics Announces Pricing of Initial Public Offering

view full story

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency
June 20, 2017

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

view full story

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts
June 19, 2017

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

view full story

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)
June 12, 2017

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)

view full story

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species
June 5, 2017

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

view full story

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis
June 4, 2017

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

view full story

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
June 3, 2017

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

view full story

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

view full story

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

view full story

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
May 23, 2017

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

view full story

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update
May 22, 2017

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update

view full story

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee
May 18, 2017

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

view full story

Coherus Biosciences prevails in ‘135 IPR decision
May 16, 2017

Coherus Biosciences prevails in ‘135 IPR decision

view full story

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
April 20, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

view full story

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation
April 10, 2017

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.

view full story

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel
April 6, 2017

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment

view full story

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy
April 3, 2017

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

view full story

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102
March 29, 2017

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting

view full story

Aeglea Biotherapeutics to Present Topline Data
March 23, 2017

Aeglea Biotherapeutics to Present Topline Data from Phase 1 Trial of AEB1102

view full story

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer
March 17, 2017

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer

view full story

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint
March 2, 2017

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

view full story

Symic Bio Announces Last Patient Enrolled in SHIELD Trial
February 24, 2017

Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease

view full story

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson's research
February 21, 2017

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson’s research

view full story

Protagonist Therapeutics Presents Data on Oral Peptide
February 17, 2017

Protagonist Therapeutics Presents Data on Oral Peptide

view full story